Released Nov 6, 2024, after the close
10-Q filed Nov 7, 2024, 38 days after period end · 0000950170-24-122513
Q3 2024 · 10-Q
Revenue$250.40M$250.40M +18.3% vs Q3 2023+3.5% vs Q2 2024
Net Income$32.77M$32.77M N/M vs Q3 2023−1.9% vs Q2 2024
EPS Diluted$0.20$0.20 N/M vs Q3 2023±0.0% vs Q2 2024
Operating Income$31,644,000N/M
Operating Cash Flowderived$63,246,000N/M
Free Cash Flowderived$63,176,000—
Margins · derived
Operating margin12.6%+39.9 pt vs Q3 2023
Net margin13.1%+43.9 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $250.40M | $211.70M | $130.71M | $131.61M |
| Net Income | $32.77M | -$65.18M | -$27.18M | -$14.46M |
| EPS Diluted | $0.20 | -$0.40 | -$0.17 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acadia Pharmaceuticals Inc · CIK 1070494 · Engraved from SEC EDGAR